vTv Therapeutics (VTVT) reported Thursday screening has been reinitiated in its phase 3 trial of cadisegliatin as an adjunctive treatment of type 1 diabetes following a protocol amendment.
Continuous glucose monitors will now be provided to participants to inform the primary study endpoint, which is the number of level 2 and level 3 hypoglycemic events, the company said.
The amendment shortens trial duration to six months from 12, expediting time to topline data, the company said.
"We look forward to reporting topline Phase 3 data from CATT1 in the second half of 2026," said CEO Paul Sekhri.
The shares were up over 3% in recent trading.
Price: 21.96, Change: +0.65, Percent Change: +3.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.